No Data
Express News | Bernstein: Lowered the astrazeneca target price from 200 pounds to 180 pounds.
AstraZeneca: Overcoming Short-term Challenges With Robust Long-term Potential
AstraZeneca Director Bolsters Stake With Share Purchase
Deutsche Bank Keeps Their Hold Rating on AstraZeneca (AZN)
The ADC therapy jointly developed by astrazeneca and Daiichi Sankyo has submitted a marketing application to the FDA.
On November 13, Gelonghui announced that astrazeneca and Daiichi Sankyo have submitted a Biologics License Application (BLA) for their jointly developed Trop2 targeted antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd) based on feedback from the usa FDA, seeking accelerated approval for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring epidermal growth factor receptor (EGFR) mutations, who have previously received systemic treatment (including EGFR targeted therapy).
BMO Capital Maintains AstraZeneca(AZN.US) With Buy Rating, Cuts Target Price to $88